Researchers studied children, younger than 18 years, with the flu and acute respiratory failure across 34 pediatric intensive care units from November 2008 to May 2016. They compared baseline characteristics, clinical courses and therapies in children with:
• MRSA coinfection
• Non-MRSA bacterial coinfection
• No bacterial coinfection
Of the 170 children studies, 30 had influenza-MRSA pneumonia, 61 had non-MRSA bacterial coinfections and 71 had no bacterial coinfection.
The study showed influenza-MRSA was associated with more frequent leukopenia, acute lung injury, vasopressor use, extracorporeal life support and mortality compared to either non-MRSA group. The influenza-related mortality rate was 40 percent with MRSA compared to 4.3 percent without MRSA.
Of the children with influenza-MRSA coinfection receiving vancomycin within the first 24 hours of hospitalization, mortality was 12.5 percent if the treatment included a second anti-MRSA antibiotic. Vancomycin monotherapy in the first 24 hours correlated with a 69.2 percent mortality rate.
More articles on healthcare quality:
Texas Natural Meats recalling 500 pounds of beef due to E. coli
First West Nile cases confirmed in 2018
Potential Legionella outbreak probed at Hawaii hospital
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
